Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

Interference With Quorum-Sensing Signal Biosynthesis as a Promising Therapeutic Strategy Against Multidrug-Resistant Pathogens

(2019) Osmel Fleitas Martínez et al.   Frontiers in Cellular and Infection Microbiology

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model

(2019) Joan Gómez-Junyent et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology

(2019) Ester del Barrio-Tofiño et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa

(2018) Gloria Andolina et al.   ACS Chemical Biology

MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model

(2018) Hoan N. Le et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

(2018) Veronica Rico Caballero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects

(2018) Keith A. Rodvold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis

(2018) Nicholas S. Britt et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid

(2018) Víctor M. Chávez-Jacobo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Avibactam Pharmacokinetic/Pharmacodynamic Targets

(2018) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models

(2018) Francesca Forti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses

(2018) Achim Wach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination With Imipenem and Cilastatin in Healthy Participants

(2018) Elizabeth G. Rhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Murepavadin, a novel antipseudomonal antibiotic: Pharmacokinetics, tolerability and safety in subjects with mild, moderate, and severe renal function impairment

(2018) Glenn E. Dale et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model

(2018) Cornelia B. Landersdorfer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model

(2018) M. Montero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

(2018) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa

(2018) Yu-Wei Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae

(2018) Safa S. Almarzoky Abuhussain et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin causes profound morphological alteration but minimal cytoplasmic membrane perforation in populations of Escherichia coli and Pseudomonas aeruginosa

(2018) Noëlle H. O’Driscoll et al.   ARCHIVES OF MICROBIOLOGY

Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa

(2018) Jumpei Uchiyama et al.   ARCHIVES OF VIROLOGY

Global emergence of the widespread Pseudomonas aeruginosa ST235 clone

(2018) P. Treepong et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

(2018) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Nebulization effects on structural stability of bacteriophage PEV 44

(2018) Ariel Astudillo et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Phages & antibiotic resistance: are the most abundant entities on earth ready for a comeback?

(2018) Colin Hill et al.   Future Microbiology

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

(2018) Morgan Hakki et al.   INFECTION

Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections

(2018) Laura Escolà-Vergé et al.   INFECTION

Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes

(2018) B. Dietl et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model

(2018) Islam M. Ghazi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis

(2018) Konstantinos Z. Vardakas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program

(2018) A. Stewart et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm

(2018) Raúl Recio et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015)

(2018) M.A. Pfaller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Unexpected mechanisms of resistance in Dutch Pseudomonas aeruginosa isolates collected during 14 years of surveillance

(2018) P.D. Croughs et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Intraclonal variations of resistance and phenotype in Pseudomonas aeruginosa epidemic high-risk clone ST308: A key to success within a hospital?

(2018) F. Abdouchakour et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa

(2018) Helio S Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection

(2018) Alan R Noel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

(2018) Gregory G Stone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

(2018) Krystyna M Kazmierczak et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

(2018) R. Jain et al.   Journal of Cystic Fibrosis

Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis

(2018) Konstantinos Z. Vardakas et al.   JOURNAL OF INFECTION

Pseudomonas aeruginosa PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates

(2018) D E Tabor et al.   JOURNAL OF INFECTIOUS DISEASES

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

(2018) Evelina Tacconelli et al.   LANCET INFECTIOUS DISEASES

P. aeruginosa blood stream infection isolates: A “full house” of virulence genes in isolates associated with rapid patient death and patient survival

(2018) K.L. McCarthy et al.   MICROBIAL PATHOGENESIS

Polymyxins for CNS infections: Pharmacology and neurotoxicity

(2018) Tony Velkov et al.   PHARMACOLOGY & THERAPEUTICS

Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review

(2018) Martina Rossitto et al.   Frontiers in Microbiology

The Versatile Mutational Resistome of Pseudomonas aeruginosa

(2018) Carla López-Causapé et al.   Frontiers in Microbiology

Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa

(2018) Marc Xipell et al.   Journal of Global Antimicrobial Resistance

EVALUATION OF CEFTAZIDIME-AVIBACTAM FOR SERIOUS INFECTIONS DUE TO MULTIDRUG AND EXTENSIVE DRUG RESISTANT PSEUDOMONAS AERUGINOSA

(2018) Olga Rodríguez-Núñez et al.   Journal of Global Antimicrobial Resistance

The Therapeutic Pipeline for Pseudomonas aeruginosa Infections

(2018) Lori L. Burrows   ACS Infectious Diseases

Engineering therapeutic antibodies to combat infectious diseases

(2018) Ellen K Wagner et al.   Current Opinion in Chemical Engineering

Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients

(2018) Vanessa E. Rees et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa

(2018) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam

(2018) Fernando Sanz-García et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against Pseudomonas aeruginosa: PRIMERS IV

(2018) Scott R Evans et al.   CLINICAL INFECTIOUS DISEASES

Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults

(2018) S.O. Ali et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development

(2018) Sherwin K. B. Sy et al.   CLINICAL PHARMACOKINETICS

Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

(2018) Jianguo Li et al.   CTS-Clinical and Translational Science

Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands

(2018) Manuel Díaz-Cañestro et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia

(2018) Thana Khawcharoenporn et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa

(2018) Gabriel Cabot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages

(2018) Tristan Ferry et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Intraventricular CNS treatment with Colistin-Tigecycline combination: A case series

(2018) Vasiliki Tsolaki et al.   JOURNAL OF CRITICAL CARE

Intravenous fosfomycin in patients with liver disease for extensively drug-resistant Gram-negative bacteria

(2018) Athina Pyrpasopoulou et al.   JOURNAL OF INFECTION

Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa

(2018) Anneke van der Zee et al.   Frontiers in Microbiology

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis

(2018) Mariadelfina Molinaro et al.   Infection and Drug Resistance

Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

(2018) Tze-Peng Lim et al.   Infection and Drug Resistance

Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience

(2018) Matteo Bassetti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Infections by multidrug-resistant Gram-negative Bacteria: what's new in our arsenal and what's in the pipeline?

(2018) Despoina Koulenti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

(2018) Shun-Chung Hsueh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study

(2018) Jason C Gallagher et al.   Open Forum Infectious Diseases

Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art

(2017) Alberto Enrico Maraolo et al.   Expert Review of Anti-Infective Therapy

Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa

(2017) Aurélien Dinh et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Correlation between phenotypic antibiotic susceptibility and the resistome in Pseudomonas aeruginosa

(2017) Magali Jaillard et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Unravelling the genome of a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235 reveals an integrative conjugative element housing a blaGES-6 carbapenemase

(2017) João Botelho et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16

(2017) David M Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections

(2017) Gregory G. Stone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases

(2017) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The complete nucleotide sequence of an IncP-2 megaplasmid unveils a mosaic architecture comprising a putative novel blaVIM-2-harbouring transposon in Pseudomonas aeruginosa

(2017) João Botelho et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa

(2017) Marguerite L Monogue et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

(2017) Tommaso Giani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L

(2017) Senthil Natesan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16

(2017) Andrew Walkty et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)

(2017) Michael A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

(2017) David M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

(2017) Pablo A Fraile-Ribot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of intraventricular colistin utilization: A case series

(2017) Brian Gilbert et al.   JOURNAL OF CRITICAL CARE

Long-term mortality following Pseudomonas aeruginosa bloodstream infection

(2017) K.L. McCarthy et al.   JOURNAL OF HOSPITAL INFECTION

Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections

(2017) Carlos Juan et al.   JOURNAL OF INFECTIOUS DISEASES

Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study

(2017) Silvia Gómez-Zorrilla et al.   Microbial Drug Resistance

Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance

(2017) Seth W. Dickey et al.   NATURE REVIEWS DRUG DISCOVERY

Differential Effect of Newly Isolated Phages Belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions

(2017) Simone Latz et al.   Viruses-Basel

Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps

(2017) Jorge Olivares Pacheco et al.   mBio

Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone

(2017) Carla López-Causapé et al.   Scientific Reports

The Power of Asymmetry: Architecture and Assembly of the Gram-Negative Outer Membrane Lipid Bilayer

(2016) Jeremy C. Henderson et al.   Annual Review of Microbiology

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

(2016) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates

(2016) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients

(2016) Leonie Greipel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Deciphering the resistome of the widespreadP. aeruginosaST175 international high-risk clone through whole genome sequencing

(2016) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014

(2016) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics

(2016) Yanfang Feng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B

(2016) Maria Helena Rigatto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)

(2016) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

(2016) Deanna J. Buehrle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms

(2016) Gabriel Torrens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition

(2016) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interaction of Avibactam with Class B Metallo-β-Lactamases

(2016) Martine I. Abboud et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?

(2016) Alexandre P. Zavascki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

(2016) Juan José Castón et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy

(2016) Fekade Bruck Sime et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling

(2016) Rajbharan Yadav et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa

(2016) Yuka Yamagishi et al.   CHEMOTHERAPY

Dosing guidance for intravenous colistin in critically-ill patients

(2016) Roger L Nation et al.   CLINICAL INFECTIOUS DISEASES

The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study

(2016) Yael Dishon Benattar et al.   CLINICAL INFECTIOUS DISEASES

The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.

(2016) Bruno François et al.   CLINICAL INFECTIOUS DISEASES

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Phenotype and toxicity of the recently discovered exlA -positive Pseudomonas aeruginosa strains collected worldwide

(2016) Emeline Reboud et al.   ENVIRONMENTAL MICROBIOLOGY

New β-Lactamase Inhibitors in the Clinic

(2016) Krisztina M. Papp-Wallace et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate

(2016) Juan P. Horcajada et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies

(2016) Silvia Gómez-Zorrilla et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation

(2016) O. Asuphon et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis

(2016) Oren Zusman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study

(2016) Alexandre Brasseur et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD model

(2016) Ami F. Mohamed et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

A cohort study of bacteremic pneumonia

(2016) Cristina Vazquez Guillamet et al.   MEDICINE

Quorum sensing signal–response systems in Gram-negative bacteria

(2016) Kai Papenfort et al.   NATURE REVIEWS MICROBIOLOGY

The Rrp6 C-terminal domain binds RNA and activates the nuclear RNA exosome

(2016) Elizabeth V. Wasmuth et al.   NUCLEIC ACIDS RESEARCH

The HigB/HigA toxin/antitoxin system ofPseudomonas aeruginosainfluences the virulence factors pyochelin, pyocyanin, and biofilm formation

(2016) Thammajun L. Wood et al.   MicrobiologyOpen

Utilization of Colistin for Treatment of Multidrug-ResistantPseudomonas aeruginosa

(2016) Deana M Sabuda et al.   Canadian Journal of Infectious Diseases & Medical Microbiology

Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods

(2015) Brian C. Nelson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prospective Observational Study of Prior Rectal Colonization Status as a Predictor for Subsequent Development of Pseudomonas aeruginosa Clinical Infections

(2015) Silvia Gómez-Zorrilla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

(2015) Maria Helena Rigatto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice

(2015) M. J. Melchers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1

(2015) G. L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

(2015) Wesley D. Oliver et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins

(2015) M. Berrazeg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

(2015) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan

(2015) Yoko Mano et al.   BMC MICROBIOLOGY

Targeting virulence not viability in the search for future antibacterials

(2015) Begoña Heras et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Potent and Selective Modulation of the RhlR Quorum Sensing Receptor by Using Non-native Ligands: An Emerging Target for Virulence Control inPseudomonas aeruginosa

(2015) Nora R. Eibergen et al.   CHEMBIOCHEM

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

(2015) Roger L. Nation et al.   CLINICAL INFECTIOUS DISEASES

The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria

(2015) Xian-Zhi Li et al.   CLINICAL MICROBIOLOGY REVIEWS

The increasing threat of Pseudomonas aeruginosa high-risk clones

(2015) Antonio Oliver et al.   DRUG RESISTANCE UPDATES

New promising β-lactamase inhibitors for clinical use

(2015) I. Olsen   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant Gram-negative bacteria

(2015) Luis Patricio Maskin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study

(2015) Marta Tato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia

(2015) Helio S. Sader et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

(2015) Anaïs Potron et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin and doripenem combinations againstPseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance

(2015) Neang S. Ly et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Osteoarticular infection caused by MDRPseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams

(2015) Alba Ribera et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vivoevolution of resistance ofPseudomonas aeruginosastrains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure

(2015) Mar Solé et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

High-Resolution Analysis by Whole-Genome Sequencing of an International Lineage (Sequence Type 111) of Pseudomonas aeruginosa Associated with Metallo-Carbapenemases in the United Kingdom

(2015) Jane F. Turton et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

(2015) Alan J. Xiao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

(2015) Roger L Nation et al.   LANCET INFECTIOUS DISEASES

Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung

(2015) Julio Diaz Caballero et al.   mBio

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sequence Types 235, 111, and 132 Predominate among Multidrug-Resistant Pseudomonas aeruginosa Clinical Isolates in Croatia

(2014) Marija Guzvinec et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibiotic Pressure Is a Major Risk Factor for Rectal Colonization by Multidrug-Resistant Pseudomonas aeruginosa in Critically Ill Patients

(2014) Silvia Gómez-Zorrilla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models

(2014) Paul Warrener et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin-Induced Nephrotoxicity in Mice Involves the Mitochondrial, Death Receptor, and Endoplasmic Reticulum Pathways

(2014) Chongshan Dai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2014) Tiffany R. Keepers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model

(2014) Brian D. VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa

(2014) Marisa L. Winkler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility

(2014) Veronica N. Kos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

(2014) Ken Coleman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?

(2014) R. L. Nation et al.   CLINICAL INFECTIOUS DISEASES

Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections

(2014) C. Pena et al.   CLINICAL INFECTIOUS DISEASES

Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species

(2014) S.M. Diene et al.   CLINICAL MICROBIOLOGY AND INFECTION

Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa

(2014) A.A. Witney et al.   CLINICAL MICROBIOLOGY AND INFECTION

Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China

(2014) Y. Chen et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin

(2014) A. Safarika et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria

(2014) Roberto Imberti et al.   Expert Review of Anti-Infective Therapy

Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update

(2014) Jean-Louis Vincent   Future Microbiology

Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections

(2014) G. Samonis et al.   INFECTION

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

(2014) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa

(2014) Alicia Fajardo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)

(2014) R. K. Flamm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

(2014) M. Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment of Multidrug-ResistantPseudomonas aeruginosaUsing Extended-Infusion Antimicrobial Regimens

(2014) Emily L. Heil et al.   PHARMACOTHERAPY

The Impact of Antimicrobial Resistance and Aging in VAP Outcomes: Experience from a Large Tertiary Care Center

(2014) Marios Arvanitis et al.   PLoS One

Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria

(2014) Abiola O. Olaitan et al.   Frontiers in Microbiology

Pseudomonas aeruginosaVentilator-associated Pneumonia. Predictive Factors of Treatment Failure

(2013) Benjamin Planquette et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones

(2013) Xavier Mulet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems

(2013) Oren Zusman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multiple Mutations Lead to MexXY-OprM-Dependent Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa

(2013) Sophie Guénard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Polymyxin Resistance ofPseudomonas aeruginosa phoQMutants Is Dependent on Additional Two-Component Regulatory Systems

(2013) Alina D. Gutu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combined Intravenous and Intraventricular Administration of Colistin Methanesulfonate in Critically Ill Patients with Central Nervous System Infection

(2013) Mairi Ziaka et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells

(2013) Mohammad A. K. Azad et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

(2013) Luisa Sorlí et al.   BMC INFECTIOUS DISEASES

Antibiotic Resistance inPseudomonas Aeruginosais Associated with Decreased Fitness

(2013) Zhenzhen Sun et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

(2013) H. W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Pseudomonas aeruginosa Virulence and Antimicrobial Resistance

(2013) Alan R. Hauser   CRITICAL CARE MEDICINE

Assessment of Severity of ICU-Acquired Pneumonia and Association With Etiology

(2013) Marta Di Pasquale et al.   CRITICAL CARE MEDICINE

Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality

(2013) C. Peña et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics

(2013) Tony Velkov et al.   Future Microbiology

Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa

(2013) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Selective advantages of two major clones of carbapenem-resistant Pseudomonas aeruginosa isolates (CC235 and CC641) from Korea: antimicrobial resistance, virulence and biofilm-forming activity

(2013) Ji-Young Lee et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing

(2013) D. Skurnik et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii

(2012) Qin Lu et al.   ANESTHESIOLOGY

Quantitative Contributions of Target Alteration and Decreased Drug Accumulation to Pseudomonas aeruginosa Fluoroquinolone Resistance

(2012) Sebastian Bruchmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities

(2012) Bartolomé Moyá et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

(2012) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones

(2012) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosapneumonia

(2012) So-Youn Park et al.   BMC INFECTIOUS DISEASES

Association Between Colistin Dose and Microbiologic Outcomes in Patients With Multidrug-Resistant Gram-Negative Bacteremia

(2012) Giulia Vicari et al.   CLINICAL INFECTIOUS DISEASES

Costs of Healthcare- and Community-Associated Infections With Antimicrobial-Resistant Versus Antimicrobial-Susceptible Organisms

(2012) Matthew J. Neidell et al.   CLINICAL INFECTIOUS DISEASES

High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study

(2012) L. Dalfino et al.   CLINICAL INFECTIOUS DISEASES

Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients

(2012) C. Peña et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients

(2012) Zoe E. Athanassa et al.   INTENSIVE CARE MEDICINE

Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin

(2012) Anucha Apisarnthanarak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Challenges for accurate susceptibility testing, detection and interpretation of  -lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study

(2012) C. Juan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?

(2012) Konstantinos Z. Vardakas et al.   JOURNAL OF INFECTION

Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study

(2011) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula

(2011) Phillip J. Bergen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa

(2011) G. L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth

(2011) Xavier Mulet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model

(2011) Phillip J. Bergen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections

(2011) Carmen Peña et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa

(2011) Reinout Naesens et al.   BMC INFECTIOUS DISEASES

Colistin pharmacokinetics: the fog is lifting

(2011) W. Couet et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinical outcomes of type III Pseudomonas aeruginosa bacteremia*

(2011) Ali A. El-Solh et al.   CRITICAL CARE MEDICINE

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates

(2011) G. Samonis et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Status report on carbapenemases: challenges and prospects

(2011) Gopi Patel et al.   Expert Review of Anti-Infective Therapy

Efficacy and Safety of Colistin in the Treatment of Infections Caused by Multidrug-resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancy: A Matched Pair Analysis

(2011) Nadira Durakovic et al.   INTERNAL MEDICINE

Adaptive resistance to cationic compounds in Pseudomonas aeruginosa

(2011) Anna Skiada et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The revival of fosfomycin

(2011) Argyris S. Michalopoulos et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa

(2011) K. Abdelraouf et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem

(2011) E. Riera et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Most Multidrug-Resistant Pseudomonas aeruginosa Isolates from Hospitals in Eastern France Belong to a Few Clonal Types

(2011) Pascal Cholley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Impact of Multidrug Resistance on Experimental Empyema by Pseudomonas aeruginosa

(2011) Evangelos J. Giamarellos-Bourboulis et al.   RESPIRATION

Pseudomonas aeruginosa: all roads lead to resistance

(2011) Elena B.M. Breidenstein et al.   TRENDS IN MICROBIOLOGY

Pseudomonas Aeruginosa: Resistance to the Max

(2011) Keith Poole   Frontiers in Microbiology

High-Dose Continuous Infusion β-Lactam Antibiotics for the Treatment of Resistant Pseudomonas Aeruginosa Infections in Immunocompromised Patients

(2010) Brad Moriyama et al.   ANNALS OF PHARMACOTHERAPY

Amikacin Monotherapy for Sepsis Caused by Panresistant Pseudomonas aeruginosa

(2010) B. Layeux et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and β-Lactams inPseudomonas aeruginosa

(2010) Cédric Muller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of a New Cephalosporin, CXA-101 (FR264205), against  -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression

(2010) A. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic Determinants Involved in the Susceptibility of Pseudomonas aeruginosa to  -Lactam Antibiotics

(2010) C. Alvarez-Ortega et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Serum and Cerebrospinal Fluid Levels of Colistin in Pediatric Patients

(2010) C. Antachopoulos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of High‐Dose 4‐Hour Infusion of Doripenem, in Combination with Fosfomycin, for Treatment of Carbapenem‐ResistantPseudomonas aeruginosaPneumonia

(2010) Anucha Apisarnthanarak et al.   CLINICAL INFECTIOUS DISEASES

Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections

(2010) Chien-Yu Cheng et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection

(2010) Cristina Suárez et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

New insights into the antibacterial mechanism of action of squalamine

(2010) K. Alhanout et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic

(2010) L. S. Elias et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibiotic resistance and its cost: is it possible to reverse resistance?

(2010) Dan I. Andersson et al.   NATURE REVIEWS MICROBIOLOGY

Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa

(2010) S. Han et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes

(2010) Elizabeth B Hirsch et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Quorum Sensing Inhibition Selects for Virulence and Cooperation in Pseudomonas aeruginosa

(2010) Thilo Köhler et al.   PLoS Pathogens

Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers

(2009) H. Lazar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 Pseudomonas aeruginosa Isolates Producing the Extended-Spectrum  -Lactamases GES-1 and GES-5 in Spain

(2009) E. Viedma et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Penetration of Colistin into Cerebrospinal Fluid

(2009) S. L. Markantonis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria

(2009) D. Plachouras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genomewide Identification of Genetic Determinants of Antimicrobial Drug Resistance in Pseudomonas aeruginosa

(2009) A. Dotsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains

(2009) Aleksander Deptuła et al.   ARCHIVES OF MICROBIOLOGY

Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

(2009) P. D. Lister et al.   CLINICAL MICROBIOLOGY REVIEWS

Role of Pseudomonas aeruginosa type III effectors in disease

(2009) Joanne Engel et al.   CURRENT OPINION IN MICROBIOLOGY

Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections

(2009) M. Montero et al.   INFECTION

Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies

(2009) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

(2009) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa

(2009) N. Aoki et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Structure−Activity Relationships of Polymyxin Antibiotics

(2009) Tony Velkov et al.   JOURNAL OF MEDICINAL CHEMISTRY

Management of meningitis due to antibiotic-resistant Acinetobacter species

(2009) Baek-Nam Kim et al.   LANCET INFECTIOUS DISEASES

β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein

(2009) Bartolomé Moya et al.   PLoS Pathogens

The Impact of Antimicrobial‐Resistant, Health Care–Associated Infections on Mortality in the United States

(2008) R. Monina Klevens et al.   CLINICAL INFECTIOUS DISEASES

Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies

(2008) N. Petrosillo et al.   CLINICAL MICROBIOLOGY AND INFECTION

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

(2008) M. Baer et al.   INFECTION AND IMMUNITY

Nosocomial bloodstream infections due to metallo- -lactamase-producing Pseudomonas aeruginosa

(2008) A. P. Zavascki et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY